Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Johnson & Johnson (JNJ) vs JPMorgan Ultra Short Income ETF (JPST) Price & Performance

Johnson & JohnsonTrade
JPMorgan Ultra Short Income ETFTrade

Price performance (Past 24H)

Key statistics

Johnson & Johnson vs JPMorgan Ultra Short Income ETF — how do they compare? Johnson & Johnson trades at $260.61 (market cap $626.09B), while JPMorgan Ultra Short Income ETF trades at $50.47. The key difference: Johnson & Johnson pays a 2.06% dividend while JPMorgan Ultra Short Income ETF pays none, and Johnson & Johnson is trading nearer its 52-week high, JPMorgan Ultra Short Income ETF nearer its low. Which is the better fit depends on your goals.

JNJJPST
Market Cap
$626.09B
Volume
6,156,228
Sector
HealthLeveraged / Inverse
52-Week High
$267.24$50.78
52-Week Low
$172.78$50.40
Enterprise Value
$654.37B
Dividend Yield
2.06%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Johnson & Johnson

Johnson & Johnson (JNJ) trades at $261.26, down 0.21% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and recent earnings beats. Revenue grew to $94.19B in 2025, with a net income margin of 21.48%, though cash flow turned negative due to heavy investing. The company maintains a robust dividend history, with consistent payouts and a 64-year growth streak.

Outlook remains positive with a consensus price target of $284.50, offering ~9% upside. Risks include legal headwinds and patent expirations, but analyst sentiment is bullish (52.5% buy ratings). JNJ's defensive profile and pipeline strength support long-term growth, though investors should monitor debt levels, which rose to 24.06% of assets in 2025.

JPMorgan Ultra Short Income ETF

JPST, the JPMorgan Ultra-Short Income ETF, trades at $50.465, up 0.05% with a bearish technical signal. The ETF focuses on high-quality, short-term bonds, offering a cash alternative with consistent dividends. Recent institutional buying includes Financial Management Professionals increasing its stake by 4.7% in Q2 2026 (SEC filing, August 11, 2026).

Outlook remains stable for risk-averse investors seeking yield with low volatility. Key risks include interest rate hikes and inflation pressures, as noted in Fed commentary (Zacks Investment Research, July 31, 2026). The ETF's short duration mitigates rate sensitivity, but macroeconomic shifts could impact returns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Johnson & Johnson

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.

Read more on JNJ

About JPMorgan Ultra Short Income ETF

JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.

Read more on JPST